Acura Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1935-01-01
- Employees
- 9
- Market Cap
- -
- Website
- http://www.acurapharm.com
Clinical Trials
4
Active:0
Completed:4
Trial Phases
2 Phases
Phase 2:3
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (75.0%)Phase 3
1 (25.0%)Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users
Phase 2
Completed
- Conditions
- Opioid-Related Disorders
- Interventions
- Drug: Generic H/A taken firstDrug: Vycavert taken firstDrug: Generic H/A plus p taken firstDrug: Placebo taken firstDrug: Generic H/A plus i taken first
- First Posted Date
- 2013-01-03
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Acura Pharmaceuticals Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT01759446
- Locations
- 🇺🇸
Lifetree Clinical Research, Salt Lake City, Utah, United States
Study of the Relative Abuse Potential of Acurox Tablets in Non-Dependent Recreational Opioid Users
Phase 2
Completed
- Conditions
- Opioid Abuse
- Interventions
- Drug: 80/480mg taken firstDrug: 40/0mg taken firstDrug: 80/0mg taken firstDrug: 40/240mg taken firstDrug: 0/0mg taken first
- First Posted Date
- 2009-12-11
- Last Posted Date
- 2018-11-01
- Lead Sponsor
- Acura Pharmaceuticals Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT01030406
- Locations
- 🇺🇸
Lifetree Clinical Research, Salt Lake City, Utah, United States
Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse
Phase 2
Completed
- Conditions
- Opioid Abuse
- Interventions
- Drug: Acurox 5/30mg taken first
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Acura Pharmaceuticals Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT00699010
- Locations
- 🇺🇸
Johns Hopkins Medical Center, Baltimore, Maryland, United States
Safety/Efficacy Study of Oxycodone HCl/Niacin to Treat Pain After Bunionectomy
Phase 3
Completed
- Conditions
- Pain
- Interventions
- Drug: PlaceboDrug: Acurox 5/30 mgDrug: Acurox 7.5/30
- First Posted Date
- 2008-04-07
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- Acura Pharmaceuticals Inc.
- Target Recruit Count
- 405
- Registration Number
- NCT00654069
News
No news found